KCNJ11 and neonatal diabetes mellitus: More than 90% of patients with NDM caused by KCNJ11 variants benefit from sulfonylureas (SU) treatment reporting good glycemic control (glycated hemoglobin (HbA1c): ~5.9-6.2%) and with no severe hypoglycemic episodes reported (14, 20–24).